A recent study published in the Clinical Research in Cardiology journal linked impaired high-density lipoprotein (HDL) ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, ...

Cellipont and Secretome Therapeutics are set to enter a collaboration for the manufacturing of the latter’s cellular therapy, ...